A Public Health Approach to Regulating Commercially Legalized Cannabis

Policy Statement from the American Public Health Association (APHA):
As of January 2020, 33 states, the District of Columbia, Guam, Puerto Rico and the U.S. Virgin Islands had legalized medical use of cannabis/marijuana, and 11 of those jurisdictions had legalized nonmedical adult use, typically in commercial and retail marketplaces. The federal government has not challenged laws legalizing commercial cannabis as long as states maintain strict rules regarding sales and distribution. Given the dearth of national cannabis policy research, this policy statement calls for an evidence-based public health approach to regulating and controlling the legal commerce of cannabis products that is similar in some aspects to the long established and validated framework used for tobacco and alcohol control focused on such strategies as taxation on products and regulation of advertising and marketing. Health equity and social justice are critical components of cannabis legalization. Historically, rates of cannabis-related arrests and incarcerations have been higher among Black and Latino individuals than White individuals, despite cannabis use rates being similar by race/ethnicity. Encounters with the criminal justice system negatively affect health outcomes among individuals and within communities. Racial disparities in cannabis-related criminal justice encounters are rooted in public policy. A public policy approach to ameliorating these harms is warranted. Decriminalization and implementation of public health regulatory and enforcement structures must be supported by current evidence and best practices and must keep health equity and social justice at the forefront of public health policy and enforcement efforts. This policy statement is primarily focused on regulation of “commercial adult use markets” at the state level.

To read the full statement from the APHA, click here: https://www.apha.org/policies-and-advocacy/public-health-policy-statements/policy-database/2021/01/13/a-public-health-approach-to-regulating-commercially-legalized-cannabis

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents: Impacts of Maternal Cannabis Use on Long-Term Psychiatric Risk

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Medical marijuana access and prolonged opioid use among adolescents and young adults

Abstract Background and Objectives Laws liberalizing access to medical marijuana are associated with reduced opioid analgesic use among adults, but little is known about the impact of such policies on adolescents and young adults. Methods This retrospective cohort study used 2005 to 2014 claims from MarketScan® Commercial database, which covers all 50 states and Washington

Scroll to Top